Fol­low­ing some clean sweeps in PhI­II, Ab­b­Vie gets an FDA OK on its top-10 block­buster prospect Orilis­sa

One of the year’s top prospec­tive block­buster ap­provals just came through.

Ab­b­Vie $AB­BV says that they just nabbed an FDA OK for elagolix — the first new oral drug ap­proved for en­dometrio­sis pain in more than a decade. 

The drug will be rolled out in­to the mar­ket­place un­der the name Orilis­sa, which an­a­lysts tap as a like­ly $1.2 bil­lion-plus drug, fit­ting well in­to EP­Van­tage’s list of top 10 ex­per­i­men­tal drugs for 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER